Hesperidin induces antinociceptive effect in mice and its aglicone, hesperetin, binds to μ-opioid receptor and inhibits GIRK1/2 currents

Pharmacology Biochemistry and Behavior

Volumn 99, Issue 3, 2011, Pages 333-341

  Loscalzo, Leonardo M ^a,b   Yow, Tin T ^b   Wasowski, Cristina ^a   Chebib, Mary ^b   Marder, Mariel ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

opioid receptor; Antinociception; Depressant; Hesperetin; Hesperidin; Xenopus oocytes

Indexed keywords

CAFFEINE; DIAZEPAM; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FLUMAZENIL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; HESPERETIN; HESPERIDIN; KETANSERIN; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; PRAZOSIN; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HOT PLATE TEST; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LOCOMOTION; MALE; MOUSE; NONHUMAN; OOCYTE; POTASSIUM CURRENT; PRIORITY JOURNAL; ROTAROD TEST; WRITHING TEST; XENOPUS LAEVIS;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HESPERIDIN; HUMANS; MALE; MICE; PAIN MEASUREMENT; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING; RATS; RECEPTORS, OPIOID, MU; XENOPUS LAEVIS;

MUS; XENOPUS LAEVIS;

EID: 79959852201     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.05.018     Document Type: Article

References (35)

1. Bauer CK, Falk T, Schwarz JR. An endogenous inactivating inward-rectifying potassium current in oocytes of Xenopus laevis. Eur J Physiol 1996;432:812-20. (Pubitemid 26281578)
2. Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, Maassen Van Den Brink A, et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 2006;24(6):1517-34. (Pubitemid 44429881)
3. Cho J. Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. Arch Pharm Res 2006;29:699-706. (Pubitemid 44338469)
4. Coughenour LL, Maclean JR, Parker RB. A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav 1977;6:351-3. (Pubitemid 8084883)
5. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 1957;46:208-9.
6. Emim JA, Oliveira AB, Lapa AJ. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice. J Pharm Pharmacol 1994;46:118-22. (Pubitemid 24070840)
7. Fernández SP, Wasowski C, Paladini AC, Marder M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur J Pharmacol 2005;512:189-98. (Pubitemid 40544353)
8. Fernández SP, Wasowski C, Paladini AC, Marder M. Central nervous system depressant action of flavonoid glycosides. Eur J Pharmacol 2006;539:168-76. (Pubitemid 44208813)
9. Galati EM, Monforte MT, Kirjavainen S, Forestieri AM, Trovato A, Tripodo MM. Biological effects of hesperidin, a citrus flavonoid. Note I: Antiinflammatory and analgesic activity. Il Farmaco 1994;49:709-12.
10. Garg A, Garg S, Zaneveld LJD, Singla AK. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001;15:655-69. (Pubitemid 34016792)
11. + (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ann N Y Acad Sci 1996;801:95-109.
12. Ikeda K, Kobayashi T, Kumanishi T, Yano R, Sora I, Niki H. Molecular mechanisms of analgesia induced by opioids and ethanol: is the GIRK channel one of the keys? Neurosci Res 2002;44:121-31.
13. Ikeda K, Yoshii M, Sora I, Kobayashi T. Opioid receptor coupling to GIRK channels. In vitro studies using a Xenopus oocyte expression system and in vivo studies on weaver mutant mice. Methods Mol Med 2003;84:53-64.
14. Ioja E, Tourwé D, Kertész I, Tóth G, Borsodi A, Benyhe S. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles. Brain Res Bull 2007;74:119-29. (Pubitemid 47187918)
15. + channel in the rat. FEBS Lett 1994;348:139-44.
16. Katavic PL, Lamb K, Navarro H, Prisinzano TE. Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships. JNat Prod 2007;70(8): 1278-82. (Pubitemid 47401567)
17. + channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem Biophys Res Commun 1995;208:1166-73.
18. + channels by various antidepressant drugs. Neuropsychopharmacology 2004;29:1841-51.
19. Kobayashi S, Tanabe S, Sugiyama M, Konishi Y. Transepithelial transport of hesperetin and hesperidin in intestinal Caco-2 cell monolayers. Biochim Biophys Acta Biomembr 2008;1778:33-41.
20. Koster R, Anderson M, Beer EJ. Acetic acid for analgesic screening. Fed Proc 1959;18:412.
21. + channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain. J Neurosci 1996;16:7137-50.
22. Loscalzo LM, Wasowski C, Paladini AC, Marder M. Opioid receptor are involved in the sedative and antinociceptive affects of hesperidin as well as in its potentiation with benzodiazepines. Eur J Pharmacol 2008;580:306-13.
23. Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 2003;75:737-45.
24. Martínez AL, González-Trujano ME, Chávez M, Pellicer F, Moreno J, López-Muñoz FJ. Hesperidin produces antinociceptive response and synergistic interaction with ketorolac in an arthritic gout-type pain in rats. Pharmacol Biochem Behav 2011;97: 683-9.
25. Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 2004;52(21):6653-9.
26. Nielsen IL, Chee WS, Poulsen L, Offord-Cavin E, Rasmussen SE, Frederiksen H, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 2006;136 (2):404-8. (Pubitemid 43228293)
27. North RA, Williams JT, Surprenant A, Christie MJ. μ and δ receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A 1987;84: 5487-91. (Pubitemid 17129020)
28. Reuveny E, Slesinger PA, Inglese J, Morales JM, Iniguez-Lluhi JA, Lefkowitz RJ, et al. Activation of the cloned muscarinic potassium channel by G protein beta gamma subunits. Nature 1994;370:143-6. (Pubitemid 24229126)
29. Robson LE, Gillam MG, Kosterlitz HW. Species differences in the concentration and distribution of opioid binding sites. Eur J Pharmacol 1985;112:65-71. (Pubitemid 15044790)
30. Rustay NR, Wahlsten D, Crabbe JC. Influence of task parameters on rotarod performance and sensitivity to ethanol in mice. Behav Brain Res 2003;141:237-49. (Pubitemid 36542972)
31. Salvador C, Martinez M, Mora IS, Egido W, Farias JM, Gamba G, et al. Functional properties of a truncated recombinant GIRK5 potassium channel. Biochim Biophys Acta 2001;1512:135-47. (Pubitemid 32378789)
32. Scholz EP, Zitron E, Kiesecker C, Thomas D, Kathöfer S, Kreuzer J, et al. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656. Nutr Metab Cardiovasc Dis 2007;17:666-75. (Pubitemid 47588874)
33. Stone EA, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience 1999;94(4):1245-52. (Pubitemid 29509689)
34. Thomasy SM, Moeller BC, Stanley SD. Comparison of the opioid receptor binding in horse, guinea pig, and rat cerebral cortex and cerebellum. Vet Anaesth Analg 2007;34:351-8. (Pubitemid 47221187)
35. Wimpey TL, Chavkin C. Opioid activate both an inward rectifier and a novel voltage-gated potassium conductance in the hippocampal formation. Neuron 1991;6:281-9.